drugset / Trial / NCT02176252

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

NCT02176252 ↗

Phase 1 Completed 83 enrolled Ardelyx AstraZeneca · collab
NaSingle-groupQuadruple-blindTreatment

Summary

The study is designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy Japanese subjects at increasing doses given for 7 days in order to allow for including Japanese subjects in future global studies. A cohort of Caucasian subjects will be included in the study to evaluate cardiac effects, assessed by digital ECGs (dECG) recordings, also in Caucasian subjects.

Timeline

Start
2013-07
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenapanor Small molecule 15 mg —
Subject Tenapanor Small molecule 30 mg —
Subject Tenapanor Small molecule 60 mg —
Subject Tenapanor Small molecule 90 mg —
Subject Tenapanor Small molecule 180 mg —

Indications

No indication recorded.